Evidence map›Paper›PMID 41355167›Full record

ArticlemAbs2025

Engineering multispecific antibodies with complete killing selectivity through the closed-loop integration of machine learning and high-throughput experimentation.

Justin Grace, Pierre-Yves Colin, Dan Foxler, Winston Haynes, Catherine Howsham, Leo Kassimatis, Lida Mavrogonatou, Rebecca Mighell, James McClory, Michael Mullin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Justin GraceLabGenius Therapeutics, R&D, London, UK.ORCID 0009-0003-1289-3408
Pierre-Yves ColinLabGenius Therapeutics, R&D, London, UK.
Dan FoxlerLabGenius Therapeutics, R&D, London, UK.
Winston HaynesLabGenius Therapeutics, R&D, London, UK.
Catherine HowshamLabGenius Therapeutics, R&D, London, UK.
Leo KassimatisLabGenius Therapeutics, R&D, London, UK.
Lida MavrogonatouLabGenius Therapeutics, R&D, London, UK.
Rebecca MighellLabGenius Therapeutics, R&D, London, UK.
James McCloryLabGenius Therapeutics, R&D, London, UK.
Michael MullinLabGenius Therapeutics, R&D, London, UK.
Tom OgolaLabGenius Therapeutics, R&D, London, UK.
Alex TownsendLabGenius Therapeutics, R&D, London, UK.
Sujata RaviLabGenius Therapeutics, R&D, London, UK.
Leo WossnigLabGenius Therapeutics, R&D, London, UK.
Gino van HeekeLabGenius Therapeutics, R&D, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On-target, off-tumor toxicities remain a major barrier for T-cell engagers in solid tumors. We present EVA

Indexed as

High-Throughput Screening AssaysMachine LearningProtein EngineeringT-LymphocytesAntibody AffinityBayes TheoremCell Line, TumorErb-b2 Receptor Tyrosine KinasesHumansERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesArtificial IntelligenceAviditybayesian optimizationHER2machine learningMultispecific antibodiesnanobodyselectivitysingle-domain antibodiesTCEsVHH

Identifiers

PMID41355167
PMCPMC12688275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.